Canadian Federal Court Deals Blow To Pfizer

Law360, New York (July 9, 2009, 12:00 AM EDT) -- In a departure from previous rulings, a Canadian federal court has shot down a patent protecting Norvasc, dealing a blow to Pfizer Inc. in its ongoing battle to shield the blockbuster blood pressure drug from generic rivals.

On Thursday, the Federal Court of Canada nullified Pfizer's patent, Canadian Patent Number 1,321,393, which covers amlodipine besylate, the active ingredient in Norvasc, due to invalidity.

The pharmaceutical giant immediately vowed to appeal the decision to the Federal Court of Appeal of Canada while acknowledging its disappointment.

“Pfizer remains...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.